KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Gross Margin (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Gross Margin readings, the most recent being 52.71% for Q3 2025.

  • On a quarterly basis, Gross Margin fell 1381.0% to 52.71% in Q3 2025 year-over-year; TTM through Sep 2025 was 58.2%, a 2338.0% decrease, with the full-year FY2024 number at 79.36%, up 1655.0% from a year prior.
  • Gross Margin hit 52.71% in Q3 2025 for Esperion Therapeutics, down from 65.35% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 95.57% in Q2 2021 to a low of 51.3% in Q2 2022.
  • Median Gross Margin over the past 5 years was 65.35% (2025), compared with a mean of 67.38%.
  • Biggest five-year swings in Gross Margin: crashed -4428bps in 2022 and later skyrocketed 4058bps in 2024.
  • Esperion Therapeutics' Gross Margin stood at 67.05% in 2021, then grew by 16bps to 77.89% in 2022, then decreased by -17bps to 64.49% in 2023, then decreased by -2bps to 62.91% in 2024, then decreased by -16bps to 52.71% in 2025.
  • The last three reported values for Gross Margin were 52.71% (Q3 2025), 65.35% (Q2 2025), and 51.48% (Q1 2025) per Business Quant data.